aDoses of apremilast were titrated during the first week of administration

bA responder was defined as a patient achieving ≥PASI-75 in both ESTEEM 1 and ESTEEM 2 at week 32.

cAt week 32, nonresponders and partial responders (ESTEEM 1) or nonresponders (ESTEEM 2) had the option of adding topical and/or UVB therapy. The decisions could be made at week 32 only but did not need to be initiated at that visit.

Patient population: Adult patients with moderate to severe plaque psoriasis who were candidates for phototherapy or systemic therapy†

Extension phase: Patients entering a long-term extension phase could be treated through 5 years

*The use of low-potency topical corticosteroids on the face, axillae, and groin, coal tar shampoo and/or salicylic acid scalp preparations was permitted throughout the studies. In addition, at week 32, subjects who did not achieve a PASI-75 response in ESTEEM 1 or a PASI-50 response in ESTEEM 2 were permitted to use topical psoriasis therapies and/or phototherapy in addition to OTEZLA 30 mg BID.

Protocol: Global, phase 3b, placebo-controlled, double-blind, multicenter study of the safety and efficacy of OTEZLA up to 104 weeks. Patients were randomized 1:1:1 to either OTEZLA twice daily, etanercept once weekly, or placebo through week 16. At week 16, all patients crossed over to the OTEZLA arm*†

Patient population: Adult patients with chronic plaque psoriasis, for ≥12 months prior to screening, who are naïve to biologic therapy and were candidates for phototherapy and/or systemic therapy‡

‡Patient population also included inadequate response, intolerance, or contraindication to at least one conventional systemic agent and no prior exposure to a biologic for the treatment of psoriatic arthritis or psoriasis.

Psoriatic Arthritis

Disclaimer: This is an international website for OTEZLA® (apremilast). The information on this site is not country-specific. It may contain information that is outside the approved indications in the country in which you are located. If you are a US resident, please click on the US residents link at the top of this page.